Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 188,419,600
  • Shares Outstanding, K 1,765,882
  • Annual Sales, $ 45,804 M
  • Annual Income, $ 4,616 M
  • 60-Month Beta 0.83
  • Price/Sales 4.07
  • Price/Cash Flow 7.69
  • Price/Book 14.38
Trade ABBV with:

Options Overview

Details
  • Implied Volatility 28.71%
  • Historical Volatility 18.39%
  • IV Percentile 43%
  • IV Rank 20.62%
  • IV High 138.15% on 12/10/20
  • IV Low 0.29% on 12/16/20
  • Put/Call Vol Ratio 0.12
  • Today's Volume 18,850
  • Volume Avg (30-Day) 26,645
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 236,303
  • Open Int (30-Day) 277,831

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 2.76
  • Number of Estimates 7
  • High Estimate 3.01
  • Low Estimate 2.14
  • Prior Year 2.42
  • Growth Rate Est. (year over year) +14.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.15 +3.44%
on 02/12/21
109.44 -2.50%
on 02/24/21
-2.03 (-1.87%)
since 02/05/21
3-Month
101.55 +5.07%
on 12/21/20
113.41 -5.92%
on 01/13/21
-0.58 (-0.54%)
since 12/04/20
52-Week
62.55 +70.58%
on 03/23/20
113.41 -5.92%
on 01/13/21
+16.09 (+17.76%)
since 03/05/20

Most Recent Stories

More News
Why Is AbbVie (ABBV) Down 2.7% Since Last Earnings Report?

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ABBV : 106.70 (+0.99%)
4 Buy-Rated Value Stocks in the Healthcare Sector

Positive developments regarding COVID-19 vaccines, an ageing population, and optimism over cures for other serious diseases are driving healthcare stocks higher. 2020 was an outstanding year for the healthcare...

ABBV : 106.70 (+0.99%)
CVS : 70.63 (+2.11%)
GSK : 34.91 (+1.84%)
TAK : 17.47 (+0.17%)
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

LLY : 206.92 (+3.18%)
AMGN : 227.73 (+2.62%)
ABBV : 106.70 (+0.99%)
BHVN : 84.03 (+7.91%)
Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA

Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.

LXRX : 6.78 (+1.80%)
RGEN : 186.19 (+1.63%)
ABBV : 106.70 (+0.99%)
RETA : 126.92 (+1.58%)
Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout

Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion

SNY : 46.59 (+1.50%)
AZN : 48.06 (+1.76%)
PFE : 34.39 (+0.56%)
MRK : 73.13 (+1.33%)
GSK : 34.91 (+1.84%)
BAYRY : 15.4550 (+0.10%)
ABBV : 106.70 (+0.99%)
Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues

Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.

LXRX : 6.78 (+1.80%)
ABBV : 106.70 (+0.99%)
EDIT : 41.63 (+3.15%)
NBRV : 1.7900 (+2.29%)
Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia

, /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine...

AGN : 193.02 (+0.02%)
ABBV : 106.70 (+0.99%)
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis

, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA (adalimumab) for the treatment of moderately to severely active ulcerative colitis...

ABBV : 106.70 (+0.99%)
AbbVie's SKYRIZI® for the Treatment of Moderate to Severe Plaque Psoriasis now Publicly Reimbursed across Canada

AbbVie's SKYRIZI® for the Treatment of Moderate to Severe Plaque Psoriasis now Publicly Reimbursed across Canada

ABBV : 106.70 (+0.99%)
Psoriasis Treatment Market Size Anticipated to Hit USD 37,634.2 Million with 9.2% CAGR by 2026; Rising Prevalence of Psoriasis Worldwide will Promote Growth | Fortune Business Insights(TM)

The global psoriasis treatment market size is anticipated to touch USD 37,634.2 million by 2026 owing to the increasing number of psoriasis cases. Some studies say that psoriasis may further develop other...

ABBV : 106.70 (+0.99%)
LLY : 206.92 (+3.18%)
MRK : 73.13 (+1.33%)
PFE : 34.39 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

3rd Resistance Point 110.69
2nd Resistance Point 108.84
1st Resistance Point 107.77
Last Price 106.70
1st Support Level 104.85
2nd Support Level 103.00
3rd Support Level 101.93

See More

52-Week High 113.41
Last Price 106.70
Fibonacci 61.8% 93.98
Fibonacci 50% 87.98
Fibonacci 38.2% 81.98
52-Week Low 62.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar